NSCI — Nanalysis Scientific Share Price
- CA$38.50m
- CA$55.92m
- CA$28.47m
- 41
- 58
- 47
- 46
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.71 | ||
Price to Tang. Book | 21.14 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.9 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -16.98% | ||
Return on Equity | -34.55% | ||
Operating Margin | -14.4% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | 8.36 | 7.87 | 16.04 | 24.82 | 28.47 | 44.46 | 46.18 | 27.71% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The Company’s segments include Scientific Equipment and Security Services. Scientific Equipment segment conducts scientific equipment manufacturing and sales, primarily as a patent-protected technology Company that develops, manufactures, and sells magnetic resonance (MR) products for security, pharmaceutical, biotech, nutraceutical, chemical, food, materials, education, life science and medical applications. Security Services, focuses on providing security services, namely providing preventative and oncall maintenance services, as well as installation, of detection and analysis equipment. It offers commercial security equipment installation and maintenance services to a variety of customers in North America. It provides airport security equipment maintenance services in each province and territory of Canada.
Directors
- Sean Krakiwsky PRE
- Luke Caplette CFO
- Julien Mueller CTO
- Garett Leskowitz CSO
- Susanne Riegel DMK
- Neal Gallagher OTH
- Bruce Lix OTH
- Greg Mcfeetors OTH
- Heather Phillips OTH
- Matt Zamora OTH
- Martin Burian IND
- Guido Cloetens IND
- Werner Gartner IND (63)
- Michal Okoniewski IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- February 27th, 2017
- Public Since
- June 29th, 2017
- No. of Employees
- 130
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
TSX Venture Exchange
- Shares in Issue
- 113,223,375

- Address
- Unit 105, 90 Freeport Boulevard NE, CALGARY, T3J 5J9
- Web
- https://www.nanalysis.com/nsci-overview
- Phone
- +1 4037699499
- Auditors
- Ernst & Young LLP
Upcoming Events for NSCI
Nanalysis Scientific Corp Annual Shareholders Meeting
Q2 2025 Nanalysis Scientific Corp Earnings Release
Similar to NSCI
Aurora Spine
TSX Venture Exchange
CardioComm Solutions
TSX Venture Exchange
Conavi Medical
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
EvokAI Creative Labs
TSX Venture Exchange
FAQ
As of Today at 22:11 UTC, shares in Nanalysis Scientific are trading at CA$0.34. This share price information is delayed by 15 minutes.
Shares in Nanalysis Scientific last closed at CA$0.34 and the price had moved by -30% over the past 365 days. In terms of relative price strength the Nanalysis Scientific share price has underperformed the Toronto Stock Exchange 300 Composite Index by -37.77% over the past year.
The overall consensus recommendation for Nanalysis Scientific is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreNanalysis Scientific does not currently pay a dividend.
Nanalysis Scientific does not currently pay a dividend.
Nanalysis Scientific does not currently pay a dividend.
To buy shares in Nanalysis Scientific you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.34, shares in Nanalysis Scientific had a market capitalisation of CA$38.50m.
Here are the trading details for Nanalysis Scientific:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: NSCI
Based on an overall assessment of its quality, value and momentum Nanalysis Scientific is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Nanalysis Scientific is CA$1.05. That is 208.82% above the last closing price of CA$0.34.
Analysts covering Nanalysis Scientific currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.06 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nanalysis Scientific. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -18.66%.
As of the last closing price of CA$0.34, shares in Nanalysis Scientific were trading -2.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Nanalysis Scientific PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Nanalysis Scientific's management team is headed by:
- Sean Krakiwsky - PRE
- Luke Caplette - CFO
- Julien Mueller - CTO
- Garett Leskowitz - CSO
- Susanne Riegel - DMK
- Neal Gallagher - OTH
- Bruce Lix - OTH
- Greg Mcfeetors - OTH
- Heather Phillips - OTH
- Matt Zamora - OTH
- Martin Burian - IND
- Guido Cloetens - IND
- Werner Gartner - IND
- Michal Okoniewski - IND